At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Aug 14, 2026 at 08:00 ET
GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M is expected to fund operations only through Q4 2026, raising near-term financing concerns. Two Phase 1 TriKE trials are enrolling, with updates expected in 2H 2026.
- EPS -$0.11 vs consensus -$0.08 (-37.5% miss)
- Cash and equivalents $5.1M as of June 30, 2026, sufficient through Q4 2026
- R&D expenses $1.1M (up from $0.4M YoY), SG&A $3.4M (up from $1.1M YoY)
- Net loss $4.5M vs $30.2M in prior year (improvement due to non-recurring $28.7M Greenshoe liability in 2025)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access